USD 1.94
(-11.82%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | - USD | 0.0% |
2022 | - USD | 0.0% |
2021 | - USD | 0.0% |
2020 | - USD | 0.0% |
2019 | - USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | - USD | 0.0% |
2024 Q1 | - USD | 0.0% |
2023 Q1 | - USD | 0.0% |
2023 FY | - USD | 0.0% |
2023 Q3 | - USD | 0.0% |
2023 Q4 | - USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2022 Q2 | - USD | 0.0% |
2022 Q1 | - USD | 0.0% |
2022 FY | - USD | 0.0% |
2022 Q4 | - USD | 0.0% |
2022 Q3 | - USD | 0.0% |
2021 Q2 | - USD | 0.0% |
2021 FY | - USD | 0.0% |
2021 Q1 | - USD | 0.0% |
2021 Q4 | - USD | 0.0% |
2021 Q3 | - USD | 0.0% |
2020 Q4 | - USD | 0.0% |
2020 Q3 | - USD | 0.0% |
2020 FY | - USD | 0.0% |
2019 FY | - USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
AIM ImmunoTech Inc. | 202 Thousand USD | 100.0% |
Ampio Pharmaceuticals, Inc. | - USD | NaN% |
Armata Pharmaceuticals, Inc. | 4.52 Million USD | 100.0% |
Actinium Pharmaceuticals, Inc. | 81 Thousand USD | 100.0% |
Azitra, Inc. | 686 Thousand USD | 100.0% |
Can-Fite BioPharma Ltd. | 743 Thousand USD | 100.0% |
Chromocell Therapeutics Corporation | - USD | NaN% |
Calidi Biotherapeutics, Inc. | - USD | NaN% |
CEL-SCI Corporation | - USD | NaN% |
iBio, Inc. | 225 Thousand USD | 100.0% |
Lineage Cell Therapeutics, Inc. | 8.94 Million USD | 100.0% |
Matinas BioPharma Holdings, Inc. | 1.09 Million USD | 100.0% |
Navidea Biopharmaceuticals, Inc. | 65.65 Thousand USD | 100.0% |
NovaBay Pharmaceuticals, Inc. | 14.72 Million USD | 100.0% |
NanoViricides, Inc. | - USD | NaN% |
Oragenics, Inc. | 37.65 Thousand USD | 100.0% |
BiomX Inc. | -357 Thousand USD | 100.0% |
BiomX Inc. | -357 Thousand USD | 100.0% |
Protalix BioTherapeutics, Inc. | 65.49 Million USD | 100.0% |
Palatin Technologies, Inc. | 4.49 Million USD | 100.0% |
Scorpius Holdings, Inc. | 6.99 Million USD | 100.0% |